Table 1.
Baseline Patient Characteristics.
| Patient Factors | n = 1000 (%) | |
|---|---|---|
| Age (median, range) | - | 65 (20, 96) |
| Gender | M | 752 (75.2) |
| F | 248 (24.8) | |
| Tumor focality | Solitary | 427 (42.7) |
| Multifocal | 573 (57.3) | |
| Tumor distribution | Unilobar | 639 (63.9) |
| Bilobar | 361 (36.1) | |
| Prior HCC Treatment | None | 889 (89) |
| TACE | 40 (4) | |
| RFA | 15 (2) | |
| Resection | 48 (5) | |
| Liver Transplant | 6 (0.5) | |
| Tumor size (median, range) | - | 4.5 (2.7, 7.6) |
| Portal vein thrombosis | present | 270 (27.0) |
| absent | 730 (73.0) | |
| Cirrhosis | present | 816 (81.6) |
| absent | 184 (18.4) | |
| Ascites | present | 242 (24.2) |
| absent | 758 (75.8) | |
| Extra-hepatic Metastases | present | 93 (9.3) |
| absent | 907 (90.7) | |
| Number Y90 treatments (median, range) | - | 1 (1, 8) |
| Albumin (median, range) | - | 3 (2.6, 3.4) |
| Bilirubin (median, range) | - | 1.1 (0.2, 93.0) |
| Alkaline phosphatase (median, range) | - | 109 (16.0, 822.0) |
| Alpha-fetoprotein (median, range) | >100 ng/dL | 409 (41) |
| ≤100 ng/dL | 591 (59) | |
| Albumin Class | 1 (>3.5 g/dL) | 188 (18.8) |
| 2 (2.8–3.5 g/dL) | 490 (49.0) | |
| 3 (<2.8 g/dL) | 322 (32.2) | |
| Blirubin | ≤1 mg/dL | 481 (48) |
| >1mg/dL | 519 (52) | |
| Bilirubin Class | 1 | 824 (82.4) |
| 2 | 124 (12.4) | |
| 3 | 52 (5.2) | |
| ALBI | 1 | 71 (7.1) |
| 2 | 637 (63.7) | |
| 3 | 292 (29.2) | |
| CP | A | 506 (50.6) |
| B | 450 (45.0) | |
| C | 44 (4.4) | |
| BCLC | A | 263 (26.3) |
| B | 152 (15.2) | |
| C | 541 (54.1) | |
| D | 44 (4.4) | |
| ECOG | 0 | 557 (55.7) |
| 1 | 401 (40.1) | |
| 2 | 42 (4.2) | |
| Combined UNOS | T1/T2 | 368 (36.8) |
| T3 | 169 (16.9) | |
| T4a | 147 (14.7) | |
| T4b/N/M | 316 (31.6) |